Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study
Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...
Drug
Chipscreen’s Chidamide in Sight of Breakthrough Therapy Designation in China for MSS/pMMR Colorectal Cancer
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...
Simcere Pharma’s Anti-Insomnia Drug Daridorexant Meets Primary Endpoint in Phase III Clinical Trial
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced topline results from a Phase III...
ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of Timdarpacept in CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
CStone Pharmaceuticals’ Sugemalimab Receives Positive CHMP Opinion for NSCLC Treatment in Europe
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced that it has...
FDA Extends Indication for BMS’ CAR-T Therapy Breyanzi to Include Relapsed MCL in Adults
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...
Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...
Hengrui Pharmaceuticals Advances Two Drug Candidates Following NMPA Clinical Trial Green Lights
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has presented new clinical data...
Akeso Inc.’s Ivonescimab Shows Positive Interim Analysis in Phase III NSCLC Study
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced positive interim analysis...
Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...
Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury
Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced...
Zelgen Biopharmaceuticals Gets NMPA Approval for Jacktinib Vitiligo Trial in Adolescents and Adults
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received...
Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...
Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval
Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...
Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...
Alphamab Oncology’s KN046 Misses Primary Endpoint in Phase III Pancreatic Cancer Study
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced disappointing results from...
Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...